Canagliflozin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Canagliflozin: From Type 2 Diabetes Mellitus to Focal Stiff Limb Syndrome
One-Sentence Summary
Canagliflozin is an SGLT2 inhibitor originally used to treat type 2 diabetes mellitus. The TxGNN model predicts it may be effective for focal stiff limb syndrome, with a very high graph-based score. However, there are currently 0 clinical trials and 0 publications supporting this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 diabetes mellitus (the registered indication text is not available in the Singapore licence records) |
| Predicted New Indication | Focal stiff limb syndrome |
| TxGNN Prediction Score | 97.92% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available. Based on known information, canagliflozin is an SGLT2 inhibitor that lowers blood glucose by reducing renal glucose reabsorption, and its efficacy in type 2 diabetes has been established.
For the predicted indication, no established mechanistic link was identified. Focal stiff limb syndrome belongs to the stiff-person spectrum, an autoimmune/neurological disorder involving impaired GABAergic inhibition. SGLT2 inhibition has no known direct effect on this pathway. The high score is a graph-based prediction only. One possible explanation is that anti-GAD65 autoimmunity in the stiff-person spectrum is associated with autoimmune diabetes, which may create a link in the knowledge graph. This is an association, not evidence of efficacy.
The same score was given to classic stiff person syndrome (97.92%). Other predictions in the top 10 include opsismodysplasia, thiamine-responsive dysfunction syndrome, several localized lipodystrophies, pancreatic agenesis and autoimmune oophoritis. None of them has supporting trials or literature. Several of them look like diabetes-phenotype or lipodystrophy-cluster associations in the graph rather than therapeutic rationales.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN14507P | INVOKANA™ Film-Coated Tablets 300 mg | Tablet, film coated | Not available in the records |
| SIN14506P | INVOKANA™ Film-Coated Tablets 100 mg | Tablet, film coated | Not available in the records |
Both registrations are valid single-ingredient products for oral use, with no cancelled licences.
Safety Considerations
- Drug Interactions: The interaction screening returned 100 interacting drugs. Most of those shown are of moderate severity, and a few are minor. Examples include:
- Moderate: furosemide, acetazolamide, nifedipine, fosinopril, aliskiren, alfuzosin, epinephrine, phenylephrine, pseudoephedrine, salbutamol, formoterol, acebutolol, hydrocortisone, levonorgestrel, fosphenytoin, fosamprenavir, gemifloxacin and ethanol.
- Minor: topical hydrocortisone and topical alclometasone.
- Disease-specific concerns noted in the prediction analysis:
- In insulin-deficient states (e.g., pancreatic agenesis, or co-existing type 1 diabetes), SGLT2 inhibitors carry a ketoacidosis risk.
- SGLT2 inhibition carries bone and fracture-related concerns, which matter for paediatric skeletal disorders.
Please refer to the package insert for warnings and contraindications, which are not available in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a high model score but no clinical trials, no literature and no plausible mechanistic link to focal stiff limb syndrome. Evidence is at L5 (model prediction only). Safety information from the package insert is also missing.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA, which are needed before any safety screening
- Mechanism of action data for canagliflozin, to allow a proper mechanistic-link analysis
- Preclinical or mechanistic evidence linking SGLT2 inhibition to GABAergic or autoimmune pathways in stiff-person spectrum disorders
- A literature and trial search (including case reports) for canagliflozin in stiff-person spectrum disorders
- A review of the registered Singapore indication text for both licences
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.